

Ustekinumab

UNDERSTANDING YOUR TREATMENT With STELARA® (ustekinumab) or Ustekinumab

Resources available to support you on your treatment journey

Whether you're just getting started with your Ustekinumab treatment or transitioning from branded STELARA®, you'll have access to many of the same programs and support resources.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

cp-513658v1

What are STELARA® (ustekinumab) and Ustekinumab?

STELARA® and Ustekinumab are prescription medicines used to treat:

- adults and children 6 years and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills)
- adults and children 6 years and older with active psoriatic arthritis
- adults 18 years and older with moderately to severely active Crohn's disease
- adults 18 years and older with moderately to severely active ulcerative colitis


Ustekinumab is STELARA® without the brand name



Produced from the **same** cell line and at the **same** manufacturing sites as STELARA®



Approved for all of the **same** indications as STELARA® with the **same** safety and efficacy profile



Available in the **same** strengths, **same** dosage forms, and **same** routes of administration as STELARA®



Has many of the **same** programs and support resources

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

cp-513658v1

The Legacy of STELARA® (ustekinumab)/Ustekinumab

You are now among the hundreds of thousands of patients who have been prescribed STELARA® or Ustekinumab. As you begin your treatment journey, you become part of the long and strong legacy of Johnson & Johnson.



20+ YEARS

of combined clinical research and 10+ years on the market across indications.



630,000+ PATIENTS

are estimated to have been **treated with STELARA® across indications** in the US.*



230,000+ PATIENTS

are estimated to have been **treated with STELARA® for Crohn's disease or ulcerative colitis** in the US.†

CD, Crohn's disease; LAAD, Longitudinal Access and Adjudication Data; UC, ulcerative colitis.

*This is based on estimates that are based on information licensed from IQVIA: LAAD, claims, NPA, DDD for the period 2009-2023 reflecting estimates of real-world activity and based on custom methodologies developed by Johnson & Johnson. All rights reserved.

†The estimated number of patients treated with STELARA® or Ustekinumab in the United States is 187,000+ for CD and 49,000+ for UC.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.


Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

cp-513648v1

For adults with moderately to severely active CD or UC

How to Take STELARA® (ustekinumab) or Ustekinumab


STELARA® and Ustekinumab Both Start With a One-Time Intravenous (IV) Infusion (Through a Vein in the Arm) Followed by Subcutaneous Injections (Injections Under the Skin) Every 8 Weeks



ONE TIME

Treatment with STELARA® (ustekinumab) or Ustekinumab starts with a one-time IV infusion through a vein in your arm, administered by a medical professional.

The amount of medicine you'll receive is based on your body weight and it will take at least **1 hour** to receive the full dose.



Keep Going With Maintenance Injections EVERY 8 WEEKS

After the initial IV infusion, you'll receive your maintenance doses of STELARA® or Ustekinumab as an injection under the skin (subcutaneous injection) every 8 weeks.



Ustekinumab from Johnson & Johnson is the same product as STELARA®

CD, Crohn's disease; UC, ulcerative colitis.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

Johnson & Johnson

STELARA® and Ustekinumab are intended for use under the guidance and supervision of your doctor. If your doctor decides that you or a caregiver can give your injections at home, you should receive training on the right way to prepare and inject STELARA® or Ustekinumab.

Be sure to read the [Medication Guide for STELARA®](#) and the [Medication Guide for Ustekinumab](#) thoroughly prior to self-injecting. You can also sign up for additional in-person injection training and support provided by your Nurse Navigator. **Do not try to inject STELARA® or Ustekinumab yourself until you or your caregiver has been shown how to inject STELARA® or Ustekinumab by your doctor or nurse.**

cp-513658v1

For Adults with Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Stelara withMe

Once you and your doctor have decided that Ustekinumab is right for you, sign up for STELARA withMe

Ustekinumab has many of the same patient support programs as STELARA® (ustekinumab)

Prescription & Cost Support

You'll receive support to help you:

- Understand how to fill your prescriptions
- Look for options that could make your treatment more affordable



STELARA withMe Savings Program

Eligible patients using commercial or private insurance can save on out-of-pocket medicine costs for STELARA® or Ustekinumab. Eligible patients **pay as little as \$5 for each dose.**

Maximum program benefit per calendar year shall apply. Offer subject to change or end without notice. Program does not cover the cost to give you your treatment. Participate without sharing your income information. See [program requirements](#).



Nurse Navigator*

When you enroll in STELARA withMe, you'll be contacted by a dedicated Nurse Navigator, a registered nurse who's just a phone call away. Your Nurse Navigator is ready to offer support and answer your questions about STELARA® or Ustekinumab, from how to self-inject to how to make the medicine more affordable.

Call a STELARA withMe Nurse Navigator at 844-4withMe (844-494-8463), Monday through Friday, 8:00 AM to 8:00 PM ET.



Treatment Support

Your Nurse Navigator can help provide infusion support and supplemental self-injection training—once your doctor decides that you or a caregiver may give your injections of STELARA® or Ustekinumab at home. They can also offer support to help you stay on track throughout your treatment journey.

[Sign up for STELARA withMe](#)

*Nurse Navigators do not provide medical advice. Please ask your doctor any questions you have about your disease and treatment. If your doctor decides that you or a caregiver may give your injections of STELARA® or Ustekinumab at home, you should receive training on the correct way to prepare and inject your medicine.

The support and resources provided by STELARA withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Eligibility for program components may vary.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

Johnson & Johnson

cp-513658v1

Attention patients with moderately to severely active CD or UC

Bathroom Access When It's Most Urgent

In 2005, the Restroom Access Act—also known as Ally's Law—was passed. It states that retail stores that do not have a public restroom must provide access to their employee restroom to any person with a medical condition.

As of March 2025, it has been passed into law in 20 states and the District of Columbia. Included here is a restroom access card that will assert your legal right to a bathroom in those states.



States that enforce Ally's Law:

California	Louisiana	New York
Colorado	Maine	Ohio
Connecticut	Maryland	Oregon
Delaware	Massachusetts	Tennessee
District of Columbia	Michigan	Texas
Illinois	Minnesota	Washington
Kentucky	New Hampshire	Wisconsin

Connecting with others in your community

The following organization can help you learn more about your condition and help connect you with others.

Crohn's & Colitis

Restroom Access. Crohn's & Colitis Foundation. Accessed March 2025.
<https://www.crohnscolitisfoundation.org/restroom-access>

CD, Crohn's disease; UC, ulcerative colitis.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

Johnson & Johnson

For adults and pediatric patients 6 years and older with moderate to severe plaque PsO or active PsA

How to Take STELARA® (ustekinumab) or Ustekinumab



STELARA® and Ustekinumab Are Both Given as Subcutaneous Injections—Injections Under the Skin.

Adult PsO and PsA

STELARA® or Ustekinumab is a 45 mg or 90 mg injection given under the skin, as directed by your doctor. Your doctor can administer it, or you (or a caregiver) can inject it at your home after proper training. Ask your doctor about which is the right choice for you.

Pediatric PsO and PsA

STELARA® or Ustekinumab is given as an injection under the skin just 4 times a year, every 12 weeks, after 2 starter doses at Weeks 0 and 4, helping parents keep their child on a treatment schedule. In children 6 years and older, it is recommended that STELARA® or Ustekinumab be given by a healthcare provider.

Adults and pediatric patients 6 years and older will receive a total of 6 weight-based doses of STELARA® or Ustekinumab in the first year:

2 starter doses
4 weeks apart

4 maintenance doses
every 12 weeks thereafter

If your doctor decides that you or a caregiver can give your injections at home, you should receive training on the right way to prepare and inject STELARA® or Ustekinumab.

Be sure to read the [Medication Guide for STELARA® and Medication Guide for Ustekinumab](#) to learn how to prepare and inject STELARA® or Ustekinumab. **Do not try to inject STELARA® or Ustekinumab until properly trained by a healthcare provider.**



STELARA® and Ustekinumab are intended for use under the guidance and supervision of your healthcare provider. Your healthcare provider will determine the right dose of STELARA® or Ustekinumab for you, the amount for each injection, and how often you should receive it. For pediatric patients, it is recommended that STELARA® or Ustekinumab be administered by a healthcare provider.

PsA, psoriatic arthritis; PsO, psoriasis.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

Johnson & Johnson

cp-513658v1

cp-513658v1

Once you and your doctor have decided that STELARA® (ustekinumab) or Ustekinumab is right for you, sign up for STELARA withMe for dedicated support, every step of the way

STELARA withMe Is With You on Your Treatment Journey



Paying for STELARA® or Ustekinumab

STELARA withMe can identify cost support options that may help with managing your out-of-pocket costs—whether you have commercial or private health insurance, government coverage such as Medicare or Medicaid, or have no insurance coverage.

Eligible patients using commercial or private insurance can save on out-of-pocket medicine costs for STELARA® or Ustekinumab. Eligible patients **pay as little as \$5 for each dose.**

Maximum program benefit per calendar year shall apply. Offer subject to change or end without notice. Program does not cover the cost to give you your treatment. Participate without sharing your income information. [See program requirements.](#)



Getting Started

STELARA withMe can review your health plan benefits and insurance coverage for STELARA®, and offer treatment education resources.



Staying on Track

We understand how important it is for you to take the Johnson & Johnson medicine your doctor prescribed. STELARA withMe provides ongoing support that may help you stay on track with your STELARA® or Ustekinumab treatment.



Injection Support

If your doctor decides that you or a caregiver may give your injections at home, we have many injection resources to help you feel comfortable injecting at home, such as instructional videos, live nurse support, and a syringe disposal program.

[Sign up for STELARA withMe](#)

The support and resources provided by STELARA withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Eligibility for program components may vary.

Selected Important Safety Information


STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

Cost Support for Eligible Patients Using Commercial or Private Insurance

STELARA withMe Savings Program

Pay as little as \$5 per dose for your STELARA® (ustekinumab) or Ustekinumab medicine



Maximum program benefit per calendar year shall apply. Savings may apply to your co-pay, co-insurance, or deductible. Terms expire at the end of each calendar year. Offer may change or end without notice. Restrictions, including monthly maximums, may apply. Program does not cover the cost to give you your treatment. Participate without sharing your income information. See [program requirements.](#)

Cost support options for patients not covered by commercial or private insurance

If you use a government-funded healthcare program to pay for STELARA® or Ustekinumab or have no insurance coverage and need help paying for your medicine:

- STELARA withMe can provide information about other resources that may be able to help with your out-of-pocket medicine costs for STELARA® or Ustekinumab

Call us at 844-4withMe (844-494-8463) or visit [JNJwithMe.com](#) for more information about affordability programs.

Various independent co-pay assistance foundations offer financial assistance.*

*Independent co-pay assistance foundations have their own rules for eligibility, which are subject to change. We cannot guarantee a foundation will help you. STELARA withMe can only refer you to foundations that support your disease state. This information is provided as a resource for you. We do not endorse any particular foundation.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

Johnson & Johnson Patient Assistance Program

Additional Affordability Support

Patient assistance from Johnson & Johnson is available if you are uninsured or if you have commercial, employer-sponsored, or government coverage that does not fully meet your needs. You may be eligible to receive your medicine from J&J at no cost for up to one year if you meet the following requirements:

- You are uninsured or have a commercial or employer-sponsored insurance plan or government coverage, such as Medicare, Medicaid, TRICARE, U.S. Department of Veterans Affairs health care, or U.S. Department of Defense health care
- You live in the United States or a U.S. territory
- You are treated as an outpatient by a healthcare provider licensed in the U.S.
- You have been prescribed an eligible medicine from J&J
- You meet the income eligibility requirements
- **For Medicare Part D Patients Only:**
 - You spend more than 4% of your gross annual household income on prescription drugs
 - You demonstrate you are not eligible for the Low-Income Subsidy (LIS)
 - LIS requirement only applicable if your income is equal to or less than 150% of Federal Poverty Level (FPL)

To learn more about income requirements, terms & conditions, and how to enroll in the Johnson & Johnson Patient Assistance Program, please visit PatientAssistanceInfo.com/IMM or (en español) PatientAssistanceInfo.com/IMM/ES or call **877-227-3728**.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

cp-513658V1

Convenient Disposal of Used Devices

If you've received approval to inject at home and have been properly trained, you can use Safe Returns® as a simple, safe, and convenient way to dispose of your used devices—at no cost to you. After you sign up for Safe Returns®, you'll receive a certified Safe Returns® mail-back envelope in the mail, along with easy-to-follow instructions. **Get started with Safe Returns®.**

For a comprehensive list of affordability programs, visit STELARAwithMe.com or call STELARA withMe

at 844-4withMe (844-494-8463), Monday–Friday, 8:00 AM to 8:00 PM ET

The support and resources provided by STELARA withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Eligibility for program components may vary.

Selected Important Safety Information

STELARA® and Ustekinumab are not for everyone; only your doctor can decide if they're right for you. STELARA® and Ustekinumab are prescription medicines that affect your immune system. They can increase your chances of having serious side effects including serious infections, cancer, serious allergic reactions, lung inflammation, and a rare condition—posterior reversible encephalopathy syndrome. Talk to your doctor if you need a vaccine.

Please read the Important Safety Information on pages 12-15, the [Medication Guide](#) for STELARA®, and the [Medication Guide](#) for Ustekinumab to learn more about these and other risks for STELARA® and Ustekinumab. Discuss any questions you have with your doctor.

cp-513658V1

WHAT ARE STELARA® (ustekinumab) AND USTEKINUMAB?

STELARA® and Ustekinumab are prescription medicines used to treat:

- adults and children 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
- adults and children 6 years of age and older with active psoriatic arthritis.
- adults with moderately to severely active Crohn's disease.
- adults with moderately to severely active ulcerative colitis.

IMPORTANT SAFETY INFORMATION

STELARA® and Ustekinumab are prescription medicines that affect your immune system. STELARA® and Ustekinumab can increase your chance of having serious side effects, including:

Serious Infections

STELARA® and Ustekinumab may lower your ability to fight infections and may increase your risk of infections. Some people have serious infections during treatment with STELARA® or Ustekinumab, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

- Your healthcare provider should check you for TB before starting STELARA® or Ustekinumab and watch you closely for signs and symptoms of TB during treatment with STELARA® or Ustekinumab.
- If your healthcare provider feels that you are at risk for TB, you may be treated for TB before and during treatment with STELARA® or Ustekinumab

You should not start STELARA® or Ustekinumab if you have any kind of infection unless your healthcare provider says it is okay.

**Important Safety Information
continued on next page**

IMPORTANT SAFETY INFORMATION (cont'd)

Before starting STELARA® or Ustekinumab, tell your healthcare provider if you:

- think you have an infection or have symptoms of an infection such as:
 - fever, sweats, or chills
 - muscle aches
 - cough
 - shortness of breath
 - blood in phlegm
 - weight loss
 - warm, red, or painful skin or sores on your body
 - diarrhea or stomach pain
 - burning when you urinate or urinate more often than normal
 - feel very tired
- are being treated for an infection or have any open cuts.
- get a lot of infections or have infections that keep coming back.
- have TB, or have been in close contact with someone with TB.

After starting STELARA® or Ustekinumab, call your healthcare provider right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. STELARA® and Ustekinumab can make you more likely to get infections or make an infection that you have worse.

People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL-12) and interleukin 23 (IL-23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA® or Ustekinumab may also be more likely to get these infections.

Cancers

STELARA® and Ustekinumab may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your healthcare provider if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving either STELARA® or Ustekinumab. Tell your healthcare provider if you have any new skin growths.

Serious Allergic Reactions

Serious allergic reactions including death can occur. Stop using STELARA® or Ustekinumab and get medical help right away if you get any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest discomfort, trouble breathing, or skin rash.

**Important Safety Information
continued on next page**

IMPORTANT SAFETY INFORMATION (cont'd)

Posterior Reversible Encephalopathy Syndrome (PRES)

PRES is a rare condition that affects the brain and can cause death. Tell your healthcare provider right away if you get any symptoms of PRES during treatment with STELARA®, including: headache, seizures, confusion, and vision problems.

Lung Inflammation

Cases of lung inflammation have happened in some people who receive either STELARA® or Ustekinumab and may be serious. These lung problems may need to be treated in a hospital. Tell your healthcare provider right away if you develop shortness of breath or a cough that doesn't go away during treatment with STELARA® or Ustekinumab.

Before you use or receive STELARA® or Ustekinumab, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed above for serious infections or cancers.
- ever had an allergic reaction to STELARA® or Ustekinumab or any of its ingredients. Ask your healthcare provider if you are not sure.
- are allergic to latex. The needle cover on the prefilled syringe contains latex.
- have recently received or are scheduled to receive an immunization (vaccine). People who are being treated with either STELARA® or Ustekinumab should avoid receiving live vaccines. Tell your healthcare provider if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems. **You should avoid receiving the BCG vaccine during the one year before receiving either STELARA® or Ustekinumab or one year after you stop receiving either STELARA® or Ustekinumab.**
- have any new or changing lesions within psoriasis areas or on normal skin.
- are receiving or have received allergy shots, especially for serious allergic reactions.
- receive or have received phototherapy for your psoriasis.
- are pregnant or plan to become pregnant. It is not known if either STELARA® or Ustekinumab can harm your unborn baby. You and your healthcare provider should decide if you will receive STELARA® or Ustekinumab.
- are breastfeeding or plan to breastfeed. STELARA® and Ustekinumab can pass into your breast milk.
- talk to your healthcare provider about the best way to feed your baby if you receive STELARA® or Ustekinumab.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

**Important Safety Information
continued on next page**

IMPORTANT SAFETY INFORMATION (cont'd)

When prescribed STELARA® or Ustekinumab:

- Use STELARA® and Ustekinumab exactly as your healthcare provider tells you to. The healthcare provider will determine the right dose of STELARA® or Ustekinumab, the amount for each injection, and how often it should be given. Be sure to keep all scheduled follow-up appointments.
- STELARA® and Ustekinumab are intended for use under the guidance and supervision of your healthcare provider. In children, it is recommended that STELARA® and Ustekinumab be administered by a healthcare provider. If your healthcare provider decides that you or a caregiver may give your injections of STELARA® or Ustekinumab at home, you or a caregiver should receive training on the right way to prepare and inject STELARA® or Ustekinumab. Do not try to inject STELARA® or Ustekinumab until you have been shown how to inject STELARA® or Ustekinumab by healthcare provider.

The most common side effects of STELARA® and Ustekinumab include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, influenza, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, bronchitis, diarrhea, stomach pain, and joint pain. These are not all of the possible side effects with STELARA® and Ustekinumab. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for STELARA® and the full [Prescribing Information](#) and [Medication Guide](#) for Ustekinumab and discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <https://www.fda.gov/medwatch> or call 1-800-FDA-1088.

cp-513655v4

Ustekinumab

UNDERSTANDING THE RESOURCES

Available to Support You on Your STELARA® (ustekinumab) or Ustekinumab Treatment Journey

A legacy of treatment: Johnson & Johnson has been making and providing STELARA® (ustekinumab) since 2009.



**Ustekinumab from Johnson & Johnson
is the *same product* as STELARA®**



**STELARA® and Ustekinumab have many of
the same programs and support resources**

**SIGN UP FOR PERSONALIZED SUPPORT
throughout your treatment journey now**

Visit STELARAwithMe.com.

Or call us at 844-4withMe (844-494-8463),
Monday through Friday, 8:00 AM–8:00 PM ET.

The support and resources provided by STELARA withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Eligibility for program components may vary.